Rare Diseases Symptoms Automatic Extraction
Home
A random Abstract
Our Project
Our Team
Antibodies and antibody-drug conjugates in the treatment of Hodgkin lymphoma.
[hodgkin lymphoma, classical]
Hodgkin
lymphoma
(
HL
)
is
a
B
cell-derived
lymphoid
malignancy
most
often
affecting
young
adults
.
More
than
80
%
of
HL
patients
achieve
long
-term
remission
after
appropriate
first
-line
treatment
consisting
of
multiagent
chemotherapy
and
/
or
radiotherapy
(
RT
)
.
In
addition
,
approximately
50
%
of
patients
with
disease
recurrence
remain
relapse-free
after
salvage
therapy
with
high
-dose
chemotherapy
followed
by
autologous
stem
cell
transplantation
(
ASCT
)
.
However
,
patients
with
multiple
relapses
are
mostly
in
a
palliative
situation
,
and
novel
drugs
for
this
patient
group
are
needed
.
Furthermore
,
novel
less
toxic
but
equally
effective
first
-line
and
second
-line
approaches
are
required
as
therapy-related
late
sequelae
represent
a
relevant
cause
of
morbidity
and
mortality
in
HL
survivors
.
Several
antibodies
and
antibody-drug
conjugates
(
ADC
)
targeting
CD
30
and
CD
2
0
have
recently
been
evaluated
in
HL
.
Excellent
response
rates
in
heavily
pretreated
patients
were
observed
with
the
ADC
brentuximab
vedotin
directed
against
CD
30
.
Thus
,
ongoing
trials
investigate
brentuximab
vedotin
in
different
additional
indications
.
One
example
is
the
first
-line
treatment
of
advanced
HL
where
the
drug
is
currently
being
evaluated
in
combination
with
variants
of
the
first
-line
protocols
ABVD
(
adriamycin
,
bleomycin
,
vinblastine
,
dacarbazine
)
and
escalated
BEACOPP
(
bleomycin
,
etoposide
,
adriamycin
,
cyclophosphamide
,
vincristine
,
procarbazine
,
prednisone
)
.
Anti-
CD
2
0
antibodies
given
either
as
single
agent
or
in
combination
with
conventional
chemotherapy
have
also
been
investigated
and
still
undergo
investigation
in
prospective
studies
including
HL
patients
.
This
article
reviews
the
available
data
on
treatment
approaches
including
antibodies
and
ADC
in
HL
patients
.
Diseases
Validation
Diseases presenting
"different additional indications"
symptom
hodgkin lymphoma, classical
You can validate or delete this automatically detected symptom
Validate the Symptom
Delete the Symptom